IBRX NASDAQ
ImmunityBio, Inc.
1W: -7.2%
1M: -7.5%
3M: +12.1%
YTD: +286.6%
1Y: +226.8%
3Y: +524.8%
5Y: -12.5%
$8.63
+0.82 (+10.50%)
Weekly Expected Move ±11.1%
$6
$7
$8
$9
$10
Credit Risk of going bust: higher than 78% of companies Debt: 8.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.14 (down 98%), ImmunityBio, Inc. would be worth roughly what it owes.
Total debt $813.1M against a stock market value of $8.28B.
Distance to default 2.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $387.2M (short-term plus half of long-term), stock volatility 101.1%; Altman Z'' -30.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.14 (down 98%), ImmunityBio, Inc. would be worth roughly what it owes.
Total debt $813.1M against a stock market value of $8.28B.
Distance to default 2.77 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $387.2M (short-term plus half of long-term), stock volatility 101.1%; Altman Z'' -30.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.45
Bearish
0 bullish
1 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
ImmunityBio, Inc. $IBRX Stake Trimmed by Davidson Kahn Capital Management LLC
Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?
ImmunityBio Stock Earnings Estimates Lifted by HC Wainwright
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
ImmunityBio's Anktiva gains expanded bladder cancer approval
ImmunityBio (NASDAQ:IBRX) Stock Jumps 6.8% – Still a Buy?
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages
ImmunityBio (NASDAQ:IBRX) Director Cheryl Cohen Sells 81,056 Shares of Company Stock
IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick - Stocktwits
IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick
IBRX Nov 2027 12.000 call (IBRX271119C00012000) Stock Historical Prices & Data - Yahoo! Finance Canada
A director proposes selling 81,056 ImmunityBio (IBRX) shares, including 55,979 from option exercises. - Stock Titan
ImmunityBio Stock Jumps: What's Going On? - Benzinga
IBRX Stock Climbs As Chairman Backs PDS Biotechnology PIPE - StocksToTrade
These High-Voltage Stocks Are Suddenly Impossible to Ignore
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot - Yahoo Finance
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot - TradingView
SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’ - Stocktwits
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst - Stocktwits
IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger Bet
IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger Bet - TradingView
IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger Bet - Stocktwits
IBRX Stock Holds Gains As Soon‑Shiong Expands Oncology Network - StocksToTrade
ImmunityBio Shares Rise as Investors Revisit ANKTIVA Expansion and Revenue Momentum - Quiver Quantitative
Immunitybio Inc Stock (IBRX) Moved Up by 11.15% on Sep 30: What Signal Does It Send? - TradingKey
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months - Yahoo Finance
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months
IBRX Stock Grinds Higher As Chairman Expands Oncology Reach - StocksToTrade
A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)
IBRX|Immunitybio Inc|Price:9.280|Chg%:-0.160 - TradingKey
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
ImmunityBio: IBRX Stock Is Up 225% And It’s Just The Beginning! ($24 Target?) Jesper Wallstedt (k7jZus2cwY) - Unisba Media
IBRX Oct 2026 11.000 call (IBRX261002C00011000) Stock Price, News, Quote & History - Yahoo! Finance Canada
IBRX Oct 2026 7.500 call (IBRX261002C00007500) stock price, news, quote and history - Yahoo Finance UK
ImmunityBio (NASDAQ:IBRX) Stock Sees Heavy Call Option Buying
Technical Reactions to IBRX Trends in Macro Strategies - Stock Traders Daily
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
State Street Corp Grows Holdings in ImmunityBio, Inc. $IBRX
ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck - Stocktwits
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying - Stocktwits
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode
Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation Mode - fr.tradingview.com
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update - Stocktwits
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last? - Yahoo Finance
ImmunityBio (IBRX) Draws Fresh Attention, Is The Stock Still Undervalued? - simplywall.st
Tidal Investments LLC Acquires New Stake in ImmunityBio, Inc. $IBRX
ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokerages
ImmunityBio (IBRX) Moved, So What Is Drawing Fresh Attention?
SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck - Yahoo Finance
IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet - Stocktwits
IBRX Stock Eyes Worst Week Since July: New Patent Eyes Broader Anktiva Use Ahead Of Lung Cancer Conference
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts - Stocktwits
SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
AXQ Capital LP Increases Holdings in ImmunityBio, Inc. $IBRX
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue?
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report? - Yahoo Finance
Canada Pension Plan Investment Board Acquires Shares of 70,200 ImmunityBio, Inc. $IBRX
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update
ImmunityBio: ANKTIVA Is Real, The Valuation Isn't (NASDAQ:IBRX) - Seeking Alpha
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits
Bell & Brown Wealth Advisors LLC Makes New $657,000 Investment in ImmunityBio, Inc. $IBRX
Bank of America Corp DE Increases Position in ImmunityBio, Inc. $IBRX
Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom - Yahoo Finance
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - Yahoo Finance
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback - TradingView
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - Stocktwits
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - TradingView
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst - finance.yahoo.com
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise - TradingView
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan - Stock Titan
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers - TechStock²
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes - Stocktwits
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Climbs As ANKTIVA Data Spotlight Draws Traders - StocksToTrade
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Is Speculation About a Russell 1000 Shift Quietly Rewriting ImmunityBio’s (IBRX) Investment Narrative? - simplywall.st
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes - finance.yahoo.com
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
ImmunityBio (IBRX) Valuation In Focus After Russell 1000 Talk Lifts Interest - simplywall.st